Raras
Buscar doenças, sintomas, genes...
Granulomatose eosinofílica com poliangeíte
ORPHA:183CID-10 · M30.1CID-11 · 4A44.A2DOENÇA RARA

A granulomatose eosinofílica com poliangiite (EGPA), anteriormente conhecida como síndrome de Churg-Strauss, é uma vasculite sistêmica de vasos de pequeno a médio porte, caracterizada por asma, infiltrados pulmonares transitórios e hipereosinofilia.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A granulomatose eosinofílica com poliangiite (EGPA), anteriormente conhecida como síndrome de Churg-Strauss, é uma vasculite sistêmica de vasos de pequeno a médio porte, caracterizada por asma, infiltrados pulmonares transitórios e hipereosinofilia.

Pesquisas ativas
17 ensaios
59 total registrados no ClinicalTrials.gov
Publicações científicas
1.906 artigos
Último publicado: 2026 Mar

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.56
Europe
Início
Adolescent
+ adult, elderly
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: M30.1
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
7 sintomas
🫁
Pulmão
7 sintomas
❤️
Coração
6 sintomas
🫘
Rins
6 sintomas
🩸
Sangue
5 sintomas
🧬
Pele e cabelo
4 sintomas

+ 26 sintomas em outras categorias

Características mais comuns

90%prev.
Infiltrados pulmonares
Muito frequente (99-80%)
90%prev.
Autoimunidade
Muito frequente (99-80%)
90%prev.
Eosinofilia
Muito frequente (99-80%)
90%prev.
Asma
Muito frequente (99-80%)
90%prev.
Aumento da resposta inflamatória
Muito frequente (99-80%)
90%prev.
Neuropatia periférica
Muito frequente (99-80%)
67sintomas
Muito frequente (12)
Frequente (24)
Ocasional (30)
Sem dados (1)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 67 características clínicas mais associadas, ordenadas por frequência.

Infiltrados pulmonaresPulmonary infiltrates
Muito frequente (99-80%)90%
AutoimunidadeAutoimmunity
Muito frequente (99-80%)90%
EosinofiliaEosinophilia
Muito frequente (99-80%)90%
AsmaAsthma
Muito frequente (99-80%)90%
Aumento da resposta inflamatóriaIncreased inflammatory response
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.906PubMed
Últimos 10 anos200publicações
Pico2025134 papers
Linha do tempo
2026Hoje · 2026🧪 1996Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado1
3Fase 35
2Fase 23
·Pré-clínico11
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Granulomatose eosinofílica com poliangeíte

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

13 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

59 ensaios clínicos encontrados, 17 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Ensaio randomizado
Timeline de publicações
1.781 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 1.781

#1

[Successful early use of mepolizumab in eosinophilic granulomatosis with polyangiitis presenting with peripheral neuropathy and gastrointestinal bleeding].

Rinsho shinkeigaku = Clinical neurology2026 Mar 14

We report a case of a 55-year-old male with eosinophilic granulomatosis with polyangiitis (EGPA) presenting with peripheral neuropathy and gastrointestinal (GI) bleeding. Despite initial treatment with high-dose intravenous methylprednisolone and intravenous immunoglobulin, the patient's symptoms persisted, and GI bleeding worsened. Capsule endoscopy revealed multiple ulcers and erosions throughout the small intestine, and biopsies from the ileum, cecum, and skin showed marked eosinophilic infiltration. Although peripheral blood eosinophil counts were normalized, tissue eosinophilia remained evident. Early administration of mepolizumab, an anti-IL-5 monoclonal antibody, led to rapid improvement in both GI bleeding and neuropathic symptoms. This case highlights the potential role of tissue-infiltrating eosinophils in EGPA pathogenesis and suggests that mepolizumab may be effective even when blood eosinophil levels are not elevated. Early intervention with mepolizumab may be beneficial in severe or refractory EGPA cases with GI involvement, which are associated with poor prognosis and high relapse rates. Careful monitoring and timely therapeutic decisions are essential for improving outcomes in such patients.

#2

Clinical and Pathological Features of Vasculitic Neuropathy: A Single-Center Study in China.

European journal of neurology2026 Mar

Vasculitic neuropathy (VN) is a disease in which vessel inflammation happens and injures peripheral nerves. Despite increasing awareness, features of VN in mainland China are still understudied. To characterize the clinical, pathological features and outcomes of VN in mainland China, and evaluate clinicopathological correlations: METHODS: We retrospectively reviewed records of VN patients diagnosed pathologically between June 1999 and December 2024, including demographic data, clinical manifestations, biopsy features, and outcomes. 112 patients were totally included. All presented with axonal sensorimotor neuropathy, most commonly involving the tibial (90.63%) and peroneal (87.50%) nerves. Systemic VN (SVN) showed more frequent transmural inflammatory cell infiltration (ICI) than non-systemic VN (NSVN) (p = 0.046). Eosinophilic granulomatosis with polyangiitis (EGPA) was more common in VN without ICI than VN with ICI (p = 0.008). In SVN, the ICI-positive exhibited more severe distal upper limb weakness (p = 0.042) and higher thrombosis rates (p = 0.001) than ICI-negative. Of the 63 patients followed, 62 received glucocorticoids with or without immunosuppressants. Thirteen died from multi-organ complications (12 SVN and 1 NSVN), while others achieved remission. The 5-year all-survival rate was 80.23% (95% CI 66.83%- 88.66%). This first large cohort of VN in mainland China delineates its clinical-pathological features. EGPA showed a lower diagnostic yield on biopsy, suggesting diverse mechanisms of vascular injury. Nerve biopsy remains the diagnostic gold standard. The overall prognosis of VN is relatively favorable, emphasizing the need for early recognition and treatment.

#3

Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.

PloS one2026

The relationship between leukotriene receptor antagonists (LTRAs) usage and the subsequent occurrence of eosinophilic granulomatosis with polyangiitis (EGPA) remained highly polarizing and controversial in previous studies. We aimed to investigate the risk of EGPA caused by LTRAs and the potential toxicological mechanisms of LTRAs-related EGPA. In this real-world pharmacovigilance study, we collected adverse event (AE) reports of EGPA associated with LTRAs use from the U.S. FDA Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Reporting (JADER), and Canadian Vigilance Adverse Reaction (CVAR) databases. The reporting odds ratio (ROR), proportional reporting ratio (PRR), information component (IC), and empirical Bayesian geometric mean (EBGM) were calculated to quantify the strength of the association between LTRAs and EGPA. The Weibull shape parameter (WSP) test was applied to analyze time-to-onset profiles of EGPA toxicity. Network pharmacology analysis was subsequently performed to identify the central genes to determine the potential mechanisms underlying LTRAs-induced EGPA. LTRAs, including montelukast, zafirlukast, and pranlukast, exhibited a strong association with EGPA in three databases (the lower limit of 95% confidence interval (CI) for ROR > 1, PRR > 2 with χ2 values ≥4, EBGM05 > 2, and IC025 > 0). After excluding corticosteroids as concomitant medication, montelukast remained significantly associated with EGPA in the FAERS database. The median time-to-onset of EGPA associated with LTRAs was 233 (range: 76-660) days, and the WSP test indicated LTRAs had early failure-type profiles. We isolated 81 interactive target genes linking LTRAs to EGPA. Several central genes, including SRC, PTGS2, EDN1, HMOX1, KDR, and OCLN, were revealed via protein-protein interactions analysis and molecular complex detection (MCODE) algorithm. Our study revealed LTRAs could increase the risk of EGPA, and initially explored potential genes and mechanisms of LTRAs-induced EGPA. It is helpful for clinicians to be alerted to the risk of EGPA during LTRAs administration.

#4

ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.

European heart journal. Case reports2026 Feb

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary vascular resistance and right ventricular failure. Sotatercept, a novel activin receptor ligand trap, has demonstrated promising haemodynamic benefits in PAH treatment. Eosinophilic granulomatosis with polyangiitis (EGPA) is an extremely rare, Th2-driven, small-vessel vasculitis, and its overlap with PAH is scarcely reported. We report the case of a woman with heritable PAH initially stabilized with oral therapy. In 2024, after further clinical decline, subcutaneous treprostinil was initiated. Subsequently, sotatercept was added, resulting in brief clinical improvement. Within weeks, however, the patient developed severe eosinophilia and exhibited laboratory and histopathological evidence of p-ANCA-positive necrotizing vasculitis, accompanied by renal and hepatocellular dysfunction. This case suggests that sotatercept's modulation of the TGF-β pathway may unmask latent autoimmune diseases such as EGPA in predisposed individuals. Although the temporal relationship between sotatercept initiation and the onset of vasculitis is compelling, both causality and underlying molecular mechanisms remain to be elucidated. Further studies are necessary to understand the potential immunomodulatory mechanisms of sotatercept.

#5

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.

Circulation2026 Mar 03

No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. Median age at presentation was 48 years (first to third quartile, 34-59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%-48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis-associated form (13.1%) at 3 years (P=0.15). Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06447935.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.091 artigos no totalmostrando 197

2026

Benralizumab: An effective alternative in patients with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.

Medicina clinica
2026

Eosinophilic granulomatosis with polyangiitis coexisting with multiple myeloma: independent entities or coexistence? A case report.

Frontiers in immunology
2026

Beyond Classification: An Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Case.

Cureus
2026

[Successful early use of mepolizumab in eosinophilic granulomatosis with polyangiitis presenting with peripheral neuropathy and gastrointestinal bleeding].

Rinsho shinkeigaku = Clinical neurology
2026

Clinical and Pathological Features of Vasculitic Neuropathy: A Single-Center Study in China.

European journal of neurology
2026

Early benralizumab use for the successful treatment of eosinophilic granulomatosis with polyangiitis-associated peripheral neuropathy: A case report.

Internal medicine (Tokyo, Japan)
2026

Benralizumab reduces sputum ANCA in patients with eosinophilic granulomatosis with polyangiitis.

ERJ open research
2026

Epidemiology of eosinophilic granulomatosis with polyangiitis in northern Spain: A population-based study (2000-2024) and literature review.

Autoimmunity reviews
2026

Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.

PloS one
2026

Safety of Immune Checkpoint Inhibitors in Cancer Patients With Preexisting Autoimmune Vasculitis.

ACR open rheumatology
2026

Hepatic Lesions With Eosinophilic Granulomatosis With Polyangiitis.

International journal of rheumatic diseases
2026

Differential Diagnosis of Eosinophilic Lung Diseases.

The journal of allergy and clinical immunology. In practice
2026

A Case of Eosinophilic Granulomatosis with Polyangiitis Emerging During Benralizumab Therapy: Successful Management Through a Switch to Mepolizumab Therapy.

Journal of asthma and allergy
2026

Burden of eosinophilic granulomatosis with polyangiitis by disease phase and steroid-sparing effects of biologics: a real-world retrospective study in Europe.

ERJ open research
2026

Fractional Exhaled Nitric Oxide as a Novel Biomarker of Relapse in Eosinophilic Granulomatosis with Polyangiitis.

American journal of respiratory and critical care medicine
2026

Improved long-term prognosis of eosinophilic granulomatosis with polyangiitis: retrospective analysis of 87 patients after biologic therapy introduction in Japan.

Scientific reports
2026

Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances.

Current opinion in rheumatology
2026

Effectiveness of Mepolizumab in Severe Uncontrolled Asthma Associated or Not with EGPA Based on the Exacto Scale and Separ-Remas Criteria.

Journal of asthma and allergy
2026

Role of biological therapies targeting eosinophils in eosinophilic granulomatosis with polyangiitis: current evidence and future perspectives.

Current medical research and opinion
2026

Eosinophilic Granulomatosis with Polyangiitis Presenting with Intermittent Claudication.

JMA journal
2026

[RECONSIDERATION OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)].

Arerugi = [Allergy]
2026

ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.

European heart journal. Case reports
2025

Case Report: Angioimmunoblastic T-cell lymphoma initially diagnosed as eosinophilic granulomatosis with polyangiitis.

Frontiers in medicine
2026

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2026

Novel Diagnostic Approaches for Eosinophilic Lung Diseases.

The journal of allergy and clinical immunology. In practice
2026

Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.

Circulation
2026

Catastrophic antiphospholipid syndrome with eosinophilia mimicking hypereosinophilic syndromes with disseminated intravascular coagulation: a case report.

Journal of medical case reports
2025

Fatal Eosinophilic Pulmonary Vasculitis in a Neonate - The First Documented Case in the English Literature.

Annals of clinical and laboratory science
2026

NS-229, a novel Janus kinase 1 inhibitor, ameliorates eosinophilic vasculitis in an ovalbumin-induced mouse model by modulating multiple cytokine signaling pathways.

The Journal of pharmacology and experimental therapeutics
2026

ANCA-negative EGPA with migratory pulmonary masses: A case report of mepolizumab response and literature review.

Medicine
2026

Validation of the 2022 ACR/EULAR classification criteria for eosinophilic granulomatosis with polyangiitis in a Chinese cohort.

Clinical rheumatology
2025

EGPA presenting as sudden cardiac arrest: a case report and review of cardiac manifestations.

Frontiers in immunology
2025

Case Report: Triple autoimmune overlap: rheumatoid arthritis, systemic lupus erythematosus, and hypereosinophilic asthma with systemic manifestations.

Frontiers in immunology
2026

Immature leukocyte and plasma-induced cell death reveal subclinical immune activation in EGPA patients in remission.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2026

Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA): Do We Need Immunosuppressives?

The journal of allergy and clinical immunology. In practice
2026

Effectiveness, Tolerability, and Safety of Mepolizumab Injection Spacing in Patients With Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Cohort Study.

Journal of clinical rheumatology : practical reports on rheumatic &amp; musculoskeletal diseases
2025

Eosinophilic granulomatosis with polyangiitis related giant coronary aneurysm leading to acute myocardial infarction: a case report.

European heart journal. Case reports
2026

Hepatic granulomas heralding eosinophilic granulomatosis with polyangiitis overlapping with Sjögren's syndrome.

Hepatology forum
2025

A Red Eye in an Elderly Patient: A Case Report Highlighting the Importance of Urgent Diagnosis.

Cureus
2026

Intracerebral Hemorrhage During the Chronic Phase of Eosinophilic Granulomatosis With Polyangiitis: A Case Report Emphasizing Cerebrovascular Vulnerability.

Clinical case reports
2026

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice.

Allergy
2026

ANCA-associated vasculitis in the United Arab Emirates: a 17-year case series with review from Gulf literature.

Annals of Saudi medicine
2025

More Than Five Years of Sustained Remission With Mepolizumab in Adolescent-Onset Eosinophilic Granulomatosis With Polyangiitis: A Case Report.

Cureus
2026

Placoid Lesions in Eosinophilic Granulomatosis with Polyangiitis.

Ophthalmology
2026

Diaphragmatic paralysis in eosinophilic granulomatosis with polyangiitis.

Medicina clinica
2026

Eosinophilic Granulomatosis with Polyangiitis Complicated by Eosinophilic Chronic Rhinosinusitis Successfully Treated with Combination of Mepolizumab and Dupilumab: A Case Report.

Internal medicine (Tokyo, Japan)
2026

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission.

The Korean journal of internal medicine
2026

Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report.

BMC pulmonary medicine
2026

Airway immune profiles and therapeutic implications of IGF1 in eosinophilic granulomatosis with polyangiitis.

Nature communications
2025

Eosinophilic Granulomatosis with Polyangiitis Presenting as Acute Abdomen: A Rare Case Report.

Journal of inflammation research
2025

Evaluation and differential diagnosis of eosinophilia: A tertiary allergy center experience.

Tuberkuloz ve toraks
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting as Mononeuritis Multiplex in a Diabetic Patient: Diagnostic and Therapeutic Challenges.

Cureus
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting as a Mononeuritis Multiplex Mimicking Guillain-Barré Syndrome.

Cureus
2025

Analyses of Final Trends and Comorbidity of Eosinophilic Granulomatosis with Polyangiitis in Patients Hospitalized in Poland in 2014-2023.

Journal of clinical medicine
2025

Benralizumab: Bringing winds of change to eosinophil-associated diseases.

The World Allergy Organization journal
2025

ANCA-Negative Eosinophilic Granulomatosis With Polyangiitis Presenting With Duodenal Stenosis: A Case Report.

The American journal of case reports
2025

Eosinophilic granulomatosis with polyangiitis diagnosed during tezepelumab treatment for severe asthma: A case report.

Allergology international : official journal of the Japanese Society of Allergology
2025

Anti-Programmed Death-Ligand 1 Antibody-Associated Eosinophilic Granulomatosis with Polyangiitis in Non-Small Cell Lung Cancer: A Case Report.

Internal medicine (Tokyo, Japan)
2025

Granulomatosis With Polyangiitis (Wegener Granulomatosis): Then and Now.

Archives of pathology &amp; laboratory medicine
2025

Updated treatment approaches for eosinophilic granulomatosis with polyangiitis: A systematic scoping review.

Modern rheumatology
2026

Overview of Biologics Targeting Type 2 Inflammation in Respiratory Disease.

The journal of allergy and clinical immunology. In practice
2025

Inside GEMA 5.5: Expert Insights on the Latest Changes in Asthma Management.

Archivos de bronconeumologia
2025

Venous Thromboembolism May Be Increased in the Early Phases of ANCA-Associated Vasculitis and Could Be Associated With a High Body Mass Index: TR-VaS Experience.

International journal of rheumatic diseases
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting With Syphilitic-Like Palmar Erythema.

International journal of rheumatic diseases
2025

Nanomedicine-driven microRNA therapy: a precision approach for eosinophilic granulomatosis with polyangiitis.

Annals of medicine and surgery (2012)
2025

Bilateral Ischaemic Stroke in Eosinophilic Granulomatosis With Polyangiitis.

Cureus
2026

Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study.

Journal of internal medicine
2025

A case report of eosinophilic granulomatosis with polyangiitis in children with cerebella infarction as the first symptom and literature review.

Frontiers in immunology
2025

Effective Use of Mepolizumab in a Rare Case of Eosinophilic Granulomatosis With Polyangiitis Complicated by Pulmonary Tuberculosis.

Cureus
2025

Angiolymphoid Hyperplasia With Eosinophilia Vs Kimura Disease: Continuum of the Same Disease or a Distinct Entity-A Case Report With Literature Review.

Case reports in medicine
2025

Dual pathogenesis and treatment approaches for eosinophilic granulomatosis with polyangiitis: a comprehensive review.

Reumatologia
2025

RESER/NVAN: Spanish Registry of patients with ANCA- associated vasculitis: objectives and methodology.

Reumatologia clinica
2026

Adjunctive dual biologic therapy for persistent nasal symptoms in eosinophilic granulomatosis with polyangiitis (EGPA).

American journal of otolaryngology
2025

Acute Eosinophilic Myocarditis and Heart Failure As the First Manifestation of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in an Asthmatic Patient: A Diagnostic Challenge.

Cureus
2026

Glucocorticoid-free remission with simultaneous mepolizumab and rituximab in life-threatening PR3-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review.

Clinical rheumatology
2026

Eosinophilic granulomatosis with polyangiitis mimicking giant cell arteritis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2026

Prediction model to identify patients with hypereosinophilic syndrome using real-world data.

The journal of allergy and clinical immunology. Global
2025

Hypereosinophilic syndrome with pulmonary and hepatic involvement mimicking autoimmune disease.

Oxford medical case reports
2025

Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review.

International journal of molecular sciences
2025

Abdominal pain as the sole initial manifestation of ANCA-positive EGPA with myocarditis: a case report and literature review.

BMC cardiovascular disorders
2026

How to choose a biologic agent considering comorbidities of bronchial asthma.

Respiratory investigation
2025

ANCA-negative Pauci-immune Vasculitis, an Often-missed Clinical Entity: A Case Report.

The Journal of the Association of Physicians of India
2026

Early Diagnosis and Treatment in Patients With Eosinophilic Granulomatosis With Polyangiitis.

The journal of allergy and clinical immunology. In practice
2025

Distinct predictors of peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitis: KEIO-vasculitis cohort.

Seminars in arthritis and rheumatism
2025

Coronary vasospasms and other cardiac manifestations in Eosinophilic Granulomatosis with Polyangiitis: Clinical impact and frequency in a monocentre study of 103 patients.

RMD open
2025

Epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis in Lithuania, 2012-2021: a retrospective cohort study.

BMJ open
2026

Estimation of Health Utility Values for Eosinophilic Granulomatosis With Polyangiitis.

PharmacoEconomics - open
2025

Clinical, Biomarker, and Radiological Progression from Asthma to Systemic Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Study.

Journal of asthma and allergy
2026

Coronary Vasospasm in Eosinophilic Granulomatosis With Polyangiitis Presenting as Acute Coronary Syndrome Treated With Anti-IL-5.

JACC. Case reports
2026

Current definition of remission in eosinophilic granulomatosis with polyangiitis (EGPA) and future perspectives.

Allergology international : official journal of the Japanese Society of Allergology
2025

Modification of 2022 ACR/EULAR ANCA-associated vasculitis classification criteria in a Japanese cohort (J-CANVAS).

Clinical and experimental rheumatology
2025

Loeffler endocarditis in hypereosinophilic syndrome, the paradox of absent peripheral eosinophilia: a case report.

European heart journal. Case reports
2025

Chronic rhinosinusitis is a risk factor for interstitial lung disease in Sjogren's syndrome.

BMC pulmonary medicine
2025

Case Report: Sequential use of tezepelumab and mepolizumab for eosinophilic otitis media in EGPA: a steroid-sparing strategy.

Frontiers in allergy
2025

Benralizumab for adults with rare and off-label eosinophilic disorders: a 52-week prospective, single-center study.

Frontiers in immunology
2026

Pre-existing diabetes mellitus and PR3-ANCA positivity as predictors of relapse in ANCA-associated vasculitis: a retrospective cohort study.

Clinical rheumatology
2025

A presentation of recurrent cerebral ischemic stroke in eosinophilic granulomatosis with polyangiitis: a case report.

Journal of medical case reports
2026

Eosinophil Extracellular Trap Remnants as Potential Biomarkers for the Diagnosis and Activity Assessment of Otitis Media Associated With Eosinophilic Granulomatosis With Polyangiitis and Eosinophilic Otitis Media.

Otology &amp; neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
2026

Answer: Unravelling embolic stroke in eosinophilic granulomatosis with polyangiitis: insights from cardiac imaging.

European heart journal. Acute cardiovascular care
2026

Myeloperoxidase-anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis.

Scandinavian journal of rheumatology
2025

Immune cell crosstalk between ANCA-associated vasculitis and IgG4-related disease: an unresolved pathogenic link.

Frontiers in immunology
2025

Progressive Purpura in Microscopic Polyangiitis: A Case Report.

Cureus
2025

Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience.

Annals of medicine
2025

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion.

Advances in therapy
2025

[A case of eosinophilic granulomatosis with polyangiitis initially presenting with allergic rhinitis and sinusitis].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2026

Vasculitis syndromes: large vessel vasculitides and ANCA-associated vasculitides from a neuroradiologist's perspective.

Japanese journal of radiology
2025

Navigating Anesthesia for Thoracoscopic Biopsy in a Six-Year-Old Child With Eosinophilic Granulomatosis With Polyangiitis, Stroke Sequelae, and Pulmonary Collapse.

Cureus
2025

Scleritis Secondary to Eosinophilic Granulomatosis With Polyangiitis.

Journal of vitreoretinal diseases
2026

Question: Unravelling embolic stroke in eosinophilic granulomatosis with polyangiitis: insights from cardiac imaging.

European heart journal. Acute cardiovascular care
2025

Clinical management of dupilumab-induced blood eosinophilia in CRSwNP: a practical algorithm.

Rhinology
2025

Pulmonary Involvement in Eosinophilic Granulomatosis with Polyangiitis.

Journal of the Belgian Society of Radiology
2025

[Recent developments in the treatment of ANCA-associated vasculitides].

La Revue du praticien
2025

[Epidemiology and risk factors of ANCAassociated vasculitides].

La Revue du praticien
2025

[Special features of ANCA-associated vasculitides].

La Revue du praticien
2025

Two-year Outcomes of Remission Induction Therapy with Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis: A Case Series.

Internal medicine (Tokyo, Japan)
2025

Kimura Disease With Eosinophilic Granulomatosis With Polyangiitis Successfully Treated by Mepolizumab.

Clinical case reports
2025

Panuveitis Associated With Idiopathic Hypereosinophilic Syndrome.

Journal of vitreoretinal diseases
2025

Eosinophilic Lung Diseases.

Clinics in chest medicine
2025

Healthcare Resource Utilisation and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Analysis of German Insurance Claims Data.

Rheumatology and therapy
2025

Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis.

Nature reviews. Rheumatology
2026

Cauda equina neuritis in eosinophilic granulomatosis with polyangiitis.

Rheumatology (Oxford, England)
2025

Interleukin-5, Eosinophils, and Interleukin-5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review.

Journal of clinical medicine
2025

[Ear, nose and throat manifestations in ANCA-associated vasculitis].

La Revue de medecine interne
2025

Central Retinal Artery Occlusion Induced by Dupilumab: A Unique Manifestation of Eosinophilic Granulomatosis with Polyangiitis.

Internal medicine (Tokyo, Japan)
2026

Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: A subgroup analysis of the MARS study.

Modern rheumatology
2025

Antineutrophil cytoplasmic antibody related vasculitis with a unique imaging presentation of organizing pneumonia. The key role of lung ultrasound.

Multidisciplinary respiratory medicine
2025

Loeffler's Endocarditis Unveils Underlying Eosinophilic Granulomatosis With Polyangiitis.

Anatolian journal of cardiology
2026

Biologic Therapies in Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis: Targeted Therapy and Personalized Care.

Tuberculosis and respiratory diseases
2025

[TWO CASES OF MPO-ANCA-POSITIVE EGPA WITH CHRONIC RHINOSINUSITIS SHOWING DIFFERENT RESPONSES TO MEPOLIZUMAB].

Arerugi = [Allergy]
2025

Antineutrophil Cytoplasmic Antibody Negative Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Presenting as Acute Decompensated Heart Failure.

JACC. Case reports
2026

Divergent Risk Patterns of Upper Airway Inflammation in Autoimmune Diseases: A Nationwide Retrospective Analysis.

American journal of rhinology &amp; allergy
2025

Dupilumab-associated anti-glomerular basement membrane nephritis in a patient with eosinophilic granulomatosis with polyangiitis: a case report.

BMC nephrology
2025

Proteinase 3-Antineutrophil Cytoplasmic Antibody (PR3-ANCA)-Associated Vasculitis: A Case Report.

Cureus
2025

Residual Eosinophilic Inflammation of Sinonasal Mucosa Under the Maintenance Phase of Eosinophilic Granulomatosis With Polyangiitis.

Cureus
2026

Dupilumab-induced eosinophilic granulomatosis with polyangiitis mimicking giant cell arteritis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2025

[Successful benralizumab therapy for severe asthma secondary to EGPA refractory to mepolizumab].

Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
2025

Psoriasis Increases the Risk of ANCA Associated Vasculitis: Insights from A Propensity Score-Matched Study.

ImmunoTargets and therapy
2025

Eosinophilic myocarditis: case series and review of the literature.

Minerva cardiology and angiology
2025

Eosinophilic granulomatosis with polyangiitis treated with Mepolizumab and Rituximab combination therapy - a case report.

ARP rheumatology
2025

Medication adherence and real-world factors of first line induction treatment selection in ANCA-associated vasculitis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
2025

Mononeuritis Multiplex as a Diagnostic Challenge in Eosinophilic Granulomatosis With Polyangiitis: Implications of Early Versus Delayed Recognition.

Cureus
2026

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Sudden visual loss and hypereosinophilia: A case of eosinophilic granulomatosis with polyangiitis.

Modern rheumatology case reports
2025

The hypereosinophilia dilemma: what's beyond cardiac involvement?

Romanian journal of internal medicine = Revue roumaine de medecine interne
2025

"A Case of Eosinophilic Granulomatosis With Polyangiitis Presenting as Quadriplegia": A Clinical and Diagnostic Report.

Journal of investigative medicine high impact case reports
2025

[Distribution of eosinophilic granulocytes in the gastrointestinal tract in EGPA].

Zeitschrift fur Rheumatologie
2025

Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis reduced glucocorticoid dose and improved residual symptoms compared to conventional immunosuppressants: a retrospective observational study.

Rheumatology international
2025

Pulmonary nontuberculous mycobacteria disease and anti-neutrophil cytoplasmic antibody positivity: a retrospective analysis of long-term clinical outcomes including vasculitis onset.

Clinical and experimental rheumatology
2025

Clinical value at baseline and follow-up of myeloperoxidase-antibodies in ANCA-associated vasculitis.

Frontiers in immunology
2025

Eosinophilic granulomatosis with polyangiitis complicated with bullous pemphigoid.

BMJ case reports
2025

Orbital Presentation of Eosinophilic Granulomatosis with Polyangiitis: An Interventional Case Report and Literature Review.

Journal of ophthalmic &amp; vision research
2025

[Biologicals in Type-2-Inflammation - from Chronic Rhinosinusitis with Nasal Polyps to Hypereosinophilic Syndrome].

Laryngo- rhino- otologie
2025

Systematic Literature Review of Real-World Outcomes of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.

The journal of allergy and clinical immunology. In practice
2025

Benralizumab in a Patient With Refractory Eosinophilic Endocarditis.

Journal of medical cases
2025

Potential masking of new-onset or relapsed eosinophilic granulomatosis with polyangiitis during benralizumab treatment: A case series.

The journal of allergy and clinical immunology. Global
2025

A case report of fulminant eosinophilic myo-pericarditis related to checkpoint inhibitors complicated by acute heart failure and cardiac tamponade.

European heart journal. Case reports
2025

The woman with a swollen tongue : A rare case of an ANCA-negative localized eosinophil-rich granulomatous inflammation affecting solely the tongue.

HNO
2025

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab.

ACR open rheumatology
2025

Associated factors to health-related quality of life in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients: Data from the Almenara Vasculitis Cohort.

Reumatologia clinica
2025

The Way Back from Tetraplegia or, Rare Neurological Manifestations of Eosinophil Granulomatosis with Polyangiitis.

Journal of clinical medicine
2025

[Pulmonary manifestations of ANCA-associated vasculitis in imaging].

Radiologie (Heidelberg, Germany)
2025

Exact power and sample size in clinical trials with two co-primary binary endpoints.

Statistical methods in medical research
2025

Cardiac disease in patients with vasculitis.

Clinical research in cardiology : official journal of the German Cardiac Society
2025

Exploiting pleiotropy to enhance variant discovery with functional false discovery rates.

Nature computational science
2026

Upadacitinib in Eosinophilic Granulomatosis With Polyangiitis: A Clinical Case Study.

International journal of dermatology
2025

Cardiac magnetic resonance imaging analysis of cardiac involvement in eosinophilic granulomatosis with polyangiitis.

Modern rheumatology
2025

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Hidden in Acute Appendicitis: A Case Revealed Through Histopathological Examination.

Cureus
2025

Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases.

Rheumatology (Oxford, England)
2025

Clinical value of biomarkers in relation to artery size in eosinophilic granulomatosis with polyangiitis: findings from an inception cohort at a Japanese City Hospital.

Clinical rheumatology
2025

Diagnostic Salivary Gland Biopsy in Pediatric Eosinophilic Granuolmatosis with Polyangiitis.

OTO open
2025

Initial Hemorrhagic Pericardial Effusion Evolving Into Perimyocarditis: An Atypical Early Presentation of Eosinophilic Granulomatosis With Polyangiitis.

Cureus
2025

An Unusual Case of Pulmonary Embolism Leading to the Diagnosis of Eosinophilic Granulomatosis With Polyangiitis.

JACC. Case reports
2025

Unique case of mononeuritis multiplex in a patient of Eosinophilic granulomatosis with polyangiitis.

Journal of family medicine and primary care
2025

Esophageal Involvement in Eosinophilic Granulomatosis With Polyangiitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
2025

Evaluation of Nailfold Capillaroscopy as a Novel Tool in the Assessment of Eosinophilic Granulomatosis with Polyangiitis.

Journal of clinical medicine
2025

Immunological Markers Associated with Skin Manifestations of EGPA.

International journal of molecular sciences
2025

Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis.

Annals of the rheumatic diseases
2025

Septic Shock Caused by Small Bowel Ischemia in Eosinophilic Granulomatosis With Polyangiitis.

United European gastroenterology journal
2025

Clinical Burden and Costs of Anti-Neutrophil Cytoplasmic Antibody-ANCA-Associated Vasculitis: Main Findings from REDCap Registry of a University Hospital in Spain.

ClinicoEconomics and outcomes research : CEOR
2025

Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review.

Frontiers in immunology
2025

Mepolizumab treatment for eosinophilic granulomatosis with polyangiitis (EGPA) with cardiac involvement.

Rheumatology (Oxford, England)
2025

Gastrointestinal Presentation of Eosinophilic Granulomatosis with Polyangiitis, Formerly Churg-Strauss Syndrome: A Case Report.

Case reports in gastroenterology
2025

Eosinophilic Granulomatosis With Polyangiitis Presenting as Isolated Coronary Vasculitis.

JACC. Case reports
2025

Eosinophilic granulomatosis with polyangiitis and facial swelling.

European journal of dermatology : EJD
2025

In Response to Churg-Strauss Syndrome: A Case of Laryngeal Presentation.

The Laryngoscope
2025

Association Between Hearing Loss and Systemic Small-Vessel Vasculitis: Audiological Aspects Across Disease Types.

Medicina (Kaunas, Lithuania)
2025

A case of cardiac arrest and spontaneous renal hemorrhage in a male patient with persistent eosinophilia: highlighting the importance of early diagnosis of eosinophilic granulomatosis with polyangiitis.

Journal of Zhejiang University. Science. B
2025

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.

Annals of internal medicine
2025

A Rare Presentation of Bilateral Foot Drop in Anti-neutrophil Cytoplasmic Antibody (ANCA)-Negative Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Diagnostic Challenge.

Cureus
2025

Hypereosinophilic syndrome with elevated IgG4 and T-cell clonality: A report of two cases.

Open life sciences
2025

Endomyocarditis in Eosinophilic Granulomatosis With Polyangiitis: Cardiac Magnetic Resonance Imaging Highlights Treatment Success.

JACC. Case reports
2025

Refractory Coronary Vasospasms in a Patient With Eosinophilic Granulomatosis With Polyangiitis.

JACC. Case reports
2025

Dupilumab-induced Eosinophilic Granulomatosis with Polyangiitis Complicated by Peripheral Neuropathic Pain: a Case Report and Literature Review.

Journal of clinical immunology
2025

Case Report: Coadministration of TNF-α blockade as an effective adjunctive strategy in the treatment of ANCA-negative EGPA with refractory peripheral neuropathy.

Frontiers in pharmacology
2025

Giant Cell Arteritis With Atypical Features: Acute Vision Loss and Marked Eosinophilia Mimicking Systemic Vasculitis.

Cureus
2025

Myositis Associated With Eosinophilic Granulomatosis With Polyangiitis Demonstrated by FDG PET/CT.

Clinical nuclear medicine
Ver todos os 1.091 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Associação brasileira dedicada a Imunodeficiências primárias.

IJCVerificada

Pioneiro da triagem neonatal na América Latina (1976). 17 milhões de bebês triados.

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Granulomatose eosinofílica com poliangeíte

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. [Successful early use of mepolizumab in eosinophilic granulomatosis with polyangiitis presenting with peripheral neuropathy and gastrointestinal bleeding].
    Rinsho shinkeigaku = Clinical neurology· 2026· PMID 41833370mais citado
  2. Clinical and Pathological Features of Vasculitic Neuropathy: A Single-Center Study in China.
    European journal of neurology· 2026· PMID 41830313mais citado
  3. Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology.
    PloS one· 2026· PMID 41801966mais citado
  4. ANCA-associated vasculitis following sotatercept initiation in a patient with heritable pulmonary arterial hypertension and previously silent eosinophilic granulomatosis with polyangiitis: a case report.
    European heart journal. Case reports· 2026· PMID 41669318mais citado
  5. Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis.
    Circulation· 2026· PMID 41645905mais citado
  6. Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis in a Pediatric Patient.
    Cureus· 2026· PMID 41994832recente
  7. Latent Class Analysis to Explore Subtypes of EGPA: Focusing on Respiratory Involvement and Inflammation Markers.
    Arch Rheumatol· 2026· PMID 41989423recente
  8. [DIAGNOSIS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-NEGATIVE EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS BASED ON RENAL PATHOLOGICAL FINDINGS WITHOUT ASTHMA].
    Arerugi· 2026· PMID 41967936recente
  9. Ischemic stroke in eosinophilic granulomatosis with polyangiitis: a single-center retrospective cohort study.
    Clin Rheumatol· 2026· PMID 41942624recente
  10. Successful treatment of eosinophilic granulomatosis with polyangiitis and Crohn's disease with combined mepolizumab and adalimumab.
    Clin Exp Rheumatol· 2026· PMID 41930657recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:183(Orphanet)
  2. MONDO:0015943(MONDO)
  3. GARD:6111(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q32811(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Granulomatose eosinofílica com poliangeíte
Compêndio · Raras BR

Granulomatose eosinofílica com poliangeíte

ORPHA:183 · MONDO:0015943
Prevalência
1-9 / 100 000
Herança
Not applicable
CID-10
M30.1 · Poliarterite com comprometimento pulmonar [Churg-Strauss]
CID-11
Ensaios
17 ativos
Início
Adolescent, Adult, Elderly
Prevalência
1.56 (Europe)
MedGen
UMLS
C0008728
EuropePMC
Wikidata
Wikipedia
Papers 10a
Evidência
🥇 Ensaio rand.
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades